Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 10/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.32 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.32 |
| ▸ | TEAD2 | Q15562 | 2/20 | 0.32 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304696 | 0.95 | CARM1 (0.37) | CARM1P2RY1EGFRBRD9FAAH | |
| SCHEMBL305146 | 0.93 | P2RY1 (0.39) | CARM1P2RY1EGFRBRD9BRD4 | |
| SCHEMBL304286 | 0.92 | P2RY1 (0.38) | CARM1P2RY1EGFRBRD9FAAH | |
| SCHEMBL13463960 | 0.92 | CARM1 (0.36) | CARM1P2RY1EGFRBRD9FAAH | |
| SCHEMBL303798 | 0.91 | CARM1 (0.39) | CARM1P2RY1EGFRBRD9BRD4 | |
| SCHEMBL303997 | 0.91 | CARM1 (0.38) | CARM1P2RY1EGFRBRD9FAAH | |
| SCHEMBL302471 | 0.89 | TEAD1 (0.35) | CARM1P2RY1EGFRBRD9FAAH | |
| SCHEMBL306092 | 0.89 | P2RY1 (0.37) | CARM1P2RY1EGFRBRD9FAAH | |
| SCHEMBL304351 | 0.85 | CARM1 (0.38) | CARM1P2RY1EGFRBRD9FAAH | |
| SCHEMBL13463959 | 0.83 | CARM1 (0.38) | CARM1P2RY1EGFRBRD9FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328871-B1 | HEDGEHOG PATHWAY MODULATORS | NOVARTIS AG (CH) | 2020-04-01 | — | — | EP | claimed |
| US-8507491-B2 | Compounds and compositions as hedgehog pathway inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | claimed |
| JP-2012500853-A | — | — | 2012-01-12 | — | — | JP | claimed |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-23 | — | — | US | claimed |
| EP-2328871-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-08 | — | — | EP | claimed |
| WO-2010027746-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-11 | — | — | WO | claimed |
| EP-2328871-B1 | HEDGEHOG PATHWAY MODULATORS | NOVARTIS AG (CH) | 2020-04-01 | — | — | EP | disclosed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2013-11-07 | — | — | US | disclosed |
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2013-11-07 | — | — | US | disclosed |
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2013-11-07 | — | — | US | disclosed |
| US-8507491-B2 | Compounds and compositions as hedgehog pathway inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507491-B2 | Compounds and compositions as hedgehog pathway inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-23 | — | — | US | disclosed |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-23 | — | — | US | disclosed |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-23 | — | — | US | disclosed |
| EP-2328871-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010027746-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | CARM1 473/4885P2RY1 4100/4885EGFR 127/4885 |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | CARM1 824/4885P2RY1 4339/4885EGFR 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.